Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jun 3:13:923905.
doi: 10.3389/fimmu.2022.923905. eCollection 2022.

Response to Commentary: Long-term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens

Sergio Serrano-Villar  1   2   3 , Santiago Moreno  1   2
Affiliations
Comment

Response to Commentary: Long-term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens

Sergio Serrano-Villar et al. Front Immunol. .
No abstract available

Keywords: C reactive protein (CRP); D-dimer (DD); HIV; antiretroviral therapy (ART); inflammation.

PubMed Disclaimer

Conflict of interest statement

Outside the submitted work, S.S-V. reports personal fees from ViiV Healthcare, Janssen Cilag, Gilead Sciences, and MSD as well as non-financial support from ViiV Healthcare and Gilead Sciences and research grants from MSD and Gilead Sciences. SM reports grants, personal fees and non-financial support from ViiV Healthcare, personal fees and non-financial support from Janssen, grants, personal fees and non-financial support from MSD, grants, personal fees and non-financial support from Gilead, outside the submitted work.

Figures

Figure 1
Figure 1
The histograms depict the percentage of participants initiating ART in the whole cohort, the 2-drug regimen group (2DR), and the year of ART switch in the 2DR group.
See this image and copyright information in PMC

Comment on

References

    1. Llibre JM, Cahn PE, Barber TJ. Commentary: Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens. Front Immunol (2022) 13, 904689. doi: 10.3389/fimmu.2022.904689/full - DOI - PMC - PubMed
    1. Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, et al. . Substitution of Raltegravir for Ritonavir-Boosted Protease Inhibitors in HIV-Infected Patients: The SPIRAL Study. AIDS (2010) 24(11):1697–707. doi: 10.1097/QAD.0b013e32833a608a - DOI - PubMed
    1. Serrano-Villar S, Martínez-Sanz J, Ron R, Talavera-Rodríguez A, Fernández-Felix BM, Herrera S, et al. . Effects of First-Line Antiretroviral Therapy on the CD4/CD8 Ratio and CD8 Cell Counts in CoRIS: A Prospective Multicentre Cohort Study. Lancet HIV (2020) 7(8):e565–73. doi: 10.1016/S2352-3018(20)30202-2 - DOI - PubMed
    1. Osiyemi O, de Wit S, Ajana F, Bisshop F, Portilla J, Routy JP, et al. . Efficacy and Safety of Switching to Dolutegravir/Lamivudine (DTG/3TC) Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With HIV-1: Results Through Week 144 From the Phase 3, Non-Inferiority TANGO Randomized Trial. Clin Infect Dis (2022):ciac036. Epub ahead of print. doi: 10.1093/cid/ciac036 - DOI - PMC - PubMed
    1. González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, et al. . Switching From Boosted PIs to Dolutegravir Decreases Soluble CD14 and Adiponectin in High Cardiovascular Risk People Living With HIV. J Antimicrob Chemother (2021). doi: 10.1093/jac/dkab158 - DOI - PubMed